Skip to main content
. Author manuscript; available in PMC: 2019 May 17.
Published in final edited form as: Sci Transl Med. 2019 Apr 25;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012

Fig. 6. Intravenous treatment with Omomyc and combination with paclitaxel display superiority to chemotherapy in a lung adenocarcinoma xenograft model.

Fig. 6

(A) RTV is reduced in mice with established disease (H1975 xenografts) treated with Omomyc (60 mg/kg) four times per week (OMO, green dots) (n = 14 per group). (B) RTV of vehicle-treated (open circles), paclitaxel (PTX)–treated (open squares), Omomyc-treated (120 mg/kg; green dots), and combination-treated (OMO + PTX; red squares) mice measured twice per week (n = 20 per group). Mean and 95% confidence interval are shown, and statistical significance compared to vehicle-treated group at each time point was calculated by a two-tailed unpaired Student’s t test (A and B). *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.001. (C) Tumor volume at experimental endpoint (30 days). Mean and SD are shown. (D) A Kaplan-Meier survival curve is shown, and the statistical significance was determined by a log-rank test. (E and F) Ki67 (E) and CC3 (F) positivity was quantified by immunostaining at endpoint for seven representative animals per group. Median and IQR are shown.